Skip to content
Primaxin, Recarbrio(cilastatin)
Primaxin, Recarbrio (cilastatin) is a small molecule pharmaceutical. Cilastatin was first approved as Primaxin on 1985-11-26. It is used to treat bacterial endocarditis, infectious arthritis, infectious bone diseases, infectious skin diseases, and intraabdominal infections amongst others in the USA. It has been approved in Europe to treat gram-negative bacterial infections. The pharmaceutical is active against dipeptidase 1.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Combinations
Primaxin, Recarbrio (generic drugs available since 2011-12-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cilastatin sodium
+
Imipenem
Tradename
Company
Number
Date
Products
PRIMAXINMerck KGaAN-050587 RX1985-11-26
1 products, RLD, RS
Show 2 discontinued
Cilastatin sodium
+
Imipenem
+
Relebactam
Tradename
Company
Number
Date
Products
RECARBRIOMerck Sharp & DohmeN-212819 RX2019-07-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
imipenem and cilastatin imipenem and cilastatin ANDA2022-10-11
primaxinANDA, New Drug Application2020-12-21
recarbrioNew Drug Application2020-06-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial endocarditisEFO_1000830D004697—
infectious arthritisEFO_1001351D001170M00
infectious bone diseases—D001850—
infectious skin diseases—D012874—
intraabdominal infections—D059413—
respiratory tract infections—D012141J06.9
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
Expiration
Code
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO
2029-07-16GAIN
2024-07-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co
84870932029-11-19DS, DPU-2586, U-2587, U-2840
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DH: Carbapenems
— J01DH51: Imipenem and cilastatin
— J01DH56: Imipenem, cilastatin and relebactam
HCPCS
Code
Description
J0742
Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
J0743
Injection, cilastatin sodium; imipenem, per 250 mg
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ventilator-associated pneumoniaD053717EFO_1001865J95.851—131—5
Bacterial pneumoniaD018410EFO_1001272J15.9—221—5
Intraabdominal infectionsD059413—111—3
InfectionsD007239EFO_00005441——1—2
PneumoniaD011014EFO_0003106J18—1—1—2
Hematologic neoplasmsD019337———1—1
Febrile neutropeniaD064147———1—1
Methicillin-resistant staphylococcus aureusD055624———1—1
Critical illnessD016638———1—1
ObesityD009765EFO_0001073E66.9———1—1
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0—52——7
Bacterial infectionsD001424A49421——6
Iatrogenic diseaseD007049——1——1
BacteremiaD016470EFO_0003033R78.81——1——1
SinusitisD012852EFO_0007486J32——1——1
AbscessD000038EFO_0003030——1——1
CellulitisD002481EFO_0003035L03.90——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.921———2
PyelonephritisD011704EFO_1001141N10-N16—2———2
Abdominal abscessD018784EFO_1001753—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD0031411————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCILASTATIN
INNcilastatin
Description
Cilastatin is the thioether resulting from the formal oxidative coupling of the thiol group of L-cysteine with the 7-position of (2Z)-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid. It is an inhibitor of dehydropeptidase I (membrane dipeptidase, 3.4.13.19), an enzyme found in the brush border of renal tubes and responsible for degrading the antibiotic imipenem. Cilastatin is therefore administered (as the sodium salt) with imipenem to prolong the antibacterial effect of the latter by preventing its renal metabolism to inactive and potentially nephrotoxic products. Cilastatin also acts as a leukotriene D4 dipeptidase inhibitor, preventing the metabolism of leukotriene D4 to leukotriene E4. It has a role as a protease inhibitor, an EC 3.4.13.19 (membrane dipeptidase) inhibitor, a xenobiotic and an environmental contaminant. It is a non-proteinogenic L-alpha-amino acid, a L-cysteine derivative, an organic sulfide and a carboxamide. It is a conjugate acid of a cilastatin(1-).
Classification
Small molecule
Drug classenzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
Identifiers
PDB—
CAS-ID82009-34-5
RxCUI2540
ChEMBL IDCHEMBL766
ChEBI ID3697
PubChem CID6435415
DrugBankDB01597
UNII ID141A6AMN38 (ChemIDplus, GSRS)
Target
Agency Approved
DPEP1
DPEP1
Organism
Homo sapiens
Gene name
DPEP1
Gene synonyms
MDP, RDP
NCBI Gene ID
1800
Protein name
dipeptidase 1
Protein synonyms
Beta-lactamase, Dehydropeptidase-I, dipeptidase 1 (renal), hRDP, Microsomal dipeptidase, Renal dipeptidase, testicular tissue protein Li 57
Uniprot ID
Q96AK2
Mouse ortholog
Dpep1 (13479)
dipeptidase 1 (P31428)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Primaxin - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,728 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,562 adverse events reported
View more details